新型HPV自采样装置用于宫颈癌筛查的验证:宫颈与自采样筛查(CASSIS)研究
本研究在转诊阴道镜检查的女性中比较HerSwab™自采样、cobas®拭子自采样与医生采样检测HPV及CIN2+的性能。三种方法HPV检测一致性良好,HerSwab™对CIN2+的敏感性与医生采样相当,在异常细胞学转诊人群中性能 adequate。
要点
- HerSwab™自采样与医生采样HPV检测一致性良好(kappa=0.84)。
- HerSwab™自采样对CIN2+敏感性87.6%,医生采样92.4%。
- HerSwab™在异常细胞学转诊女性中对高级别病变检测性能 adequate。
核心结论
- HerSwab™在检测HPV方面与医生采样一致性良好,在因异常细胞学转诊阴道镜的女性中检测高级别病变性能 adequate。
研究设计与样本
- 在麦吉尔大学附属医院诊所因转诊阴道镜检查的女性中,随机顺序采集两次自采样(HerSwab™与cobas®拭子),随后由阴道镜医生采集宫颈样本并检查,检测HPV DNA。
主要发现
- 1217名入组女性中1076名有完整HPV和细胞学结果;148名(13.8%)为CIN1,147名(13.7%)为CIN2/3,5名(0.5%)为癌。
- HPV检测一致性:HerSwab™与医生采样kappa=0.84;cobas®拭子与医生采样kappa=0.81;HerSwab™与cobas®拭子kappa=0.87。
- HerSwab™自采样对CIN2+敏感性87.6%(95%CI:79.8-93.2),cobas®拭子自采样88.6%(95%CI:80.9-94.0),医生采样92.4%(95%CI:85.5-96.7)。
- 对应特异性分别为58.1%(95%CI:54.1-62.1)、55.0%(95%CI:50.9-59.0)和58.7%(95%CI:54.6-62.6)。
- 医生采集标本的细胞学(ASC-US或更严重)对CIN2+敏感性80.2%(95%CI:70.8-87.6),特异性61.4%(95%CI:57.2-65.5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We compared the self-sampling performance of the newly designed HerSwab™ device with a physician-collected cervical sample and another self-sample using the cobas® PCR Female swab for the detection of cervical intraepithelial neoplasia (CIN) and cancer. METHODS: Women referred for colposcopy at McGill University affiliated hospital clinics collected two consecutive self-samples, one with HerSwab™ and one with cobas® swab, after receiving instructions. The order of sampling was randomized. The colposcopist then collected a cervical sample and conducted a colposcopic examination. Samples were tested for human papillomavirus (HPV) DNA. Sensitivity and specificity to detect CIN2+ and respective 95% confidence intervals (CI) were calculated to compare sampling approaches. The HPV testing agreement between samples was measured using the Kappa statistic. RESULTS: Of 1217 women enrolled, 1076 had complete results for HPV and cytology; 148 (13.8%) had CIN1, 147 (13.7%) had CIN2/3, and 5 (0.5%) had cancer. There was very good agreement between methods for HPV detection (HerSwab™ versus physician: kappa=0.84; cobas® swabs versus physician: kappa=0.81; HerSwab™ versus cobas® swabs: kappa=0.87). The sensitivity of HPV detection for CIN2+ was 87.6% (95%CI: 79.8-93.2) with self-sampling using HerSwab™, 88.6% (95%CI: 80.9-94.0) with self-sampling using the cobas® swab, and 92.4% (95%CI: 85.5-96.7) with physician sampling. Corresponding estimates of specificity were 58.1% (95%CI: 54.1-62.1), 55.0% (95%CI: 50.9-59.0) and 58.7% (95%CI: 54.6-62.6). Cytology (ASC-US or more severe) done on the physician-collected specimen was 80.2% (95%CI: 70.8-87.6) sensitive and 61.4% (95%CI: 57.2-65.5) specific for CIN2+. CONCLUSIONS: The HerSwab™ had good agreement with physician sampling in detecting HPV, and adequate performance in detecting high-grade lesions among women referred to colposcopy for abnormal cytology.
引用
- El-Zein M, Bouten S, Louvanto K, et al. Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study. Gynecol Oncol. 2018. PMID: 29678360. doi:10.1016/j.ygyno.2018.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。